Literature DB >> 6600944

Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells.

A Cohen, J W Lee, E W Gelfand.   

Abstract

Deoxyguanosine is selectively cytotoxic to leukemic cells from patients with T-acute lymphoblastic leukemia (T-ALL), whereas all other leukemic cell types were significantly less sensitive. Arabinosylguanine, a deoxyguanosine analog resistant to cleavage by purine nucleoside phosphorylase, is a more potent inhibitor of DNA synthesis in T-leukemic cells than deoxyguanosine and retains a selective cytotoxic activity for T-leukemic cells. Deoxyguanosine and arabinosylguanine are phosphorylated to deoxyGTP and arabinosylGTP, respectively, by T cells but not by other cell types. The phosphorylation and the cytotoxicity of arabinosylguanine are prevented by deoxycytidine. The selectivity of arabinosylguanine for malignant T cells, the exquisite sensitivity of these cells to the drug, and the failure of PNP to cleave the nucleoside indicate its potential in the treatment of T-ALL.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6600944

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Cloning and expression of human deoxyguanosine kinase cDNA.

Authors:  M Johansson; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  Relapsed T Cell ALL: Current Approaches and New Directions.

Authors:  Christine M McMahon; Selina M Luger
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

3.  Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

Authors:  Kumudha Balakrishnan; Jan A Burger; Maite P Quiroga; Marina Henneberg; Mary L Ayres; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

Review 4.  The discovery of first-in-class drugs: origins and evolution.

Authors:  Jörg Eder; Richard Sedrani; Christian Wiesmann
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

5.  A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Authors:  Varsha Gandhi; John M Kilpatrick; William Plunkett; Mary Ayres; Leigh Harman; Min Du; Shanta Bantia; Jan Davisson; William G Wierda; Stefan Faderl; Hagop Kantarjian; Deborah Thomas
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 6.  Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Tapan M Kadia; Varsha Gandhi
Journal:  Expert Rev Hematol       Date:  2016-12-08       Impact factor: 2.929

Review 7.  Recent Advances in the Management of Acute Lymphoblastic Leukaemia.

Authors:  Katharine A Hodby; David I Marks
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

8.  Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Authors:  Kumudha Balakrishnan; Farhad Ravandi; Shanta Bantia; Anna Franklin; Varsha Gandhi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-15

Review 9.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer.

Authors:  William B Parker
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

10.  Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts.

Authors:  B Ullman; D W Martin
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.